Filing Flows › CV Sciences (CVSI) › Q2 2026 › vs Q2 2025
CV Sciences (CVSI) Q2 2026 vs Q2 2025 (year over year)
CV Sciences's revenue fell $635K (-18%) from $3.6M in Q2 2025 to $3.0M in Q2 2026.
CV Sciences, Q2 2026: revenue $3.0M (-18% year over year), operating margin -10.1%, net loss $775K, operating cash flow $20K. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 0.4% | 6.6% | -6.1 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $3.0M | $3.6M | −$635K | -18% |
| Net loss | $775K | $261K | $514K | +197% |
| Costs & expenses | $3.8M | $3.9M | −$121K | -3% |
| Operating costs | $3.3M | $3.8M | −$465K | -12% |
| Interest & other, net | $469K | $130K | $339K | +261% |
| Income tax | $5K | $0 | $5K | — |
| Cost of revenue | $1.5M | $1.8M | −$241K | -14% |
| Research & development | $18K | $50K | −$32K | -64% |
| SG&A | $1.7M | $1.9M | −$192K | -10% |
| Operating cash sources | $795K | $548K | $247K | +45% |
| Depreciation & amortization | $22K | $58K | −$36K | -62% |
| Share-based compensation | $148K | $132K | $16K | +12% |
| Working capital & other | $625K | $358K | $267K | +75% |
| Net loss absorbed | $775K | $261K | $514K | +197% |
| Operating cash flow | $20K | $287K | −$267K | -93% |
| Free cash flow (OCF − capex) | $13K | $238K | −$225K | -95% |
| Capital expenditures | $7K | $49K | −$42K | -86% |
Questions
How much did CV Sciences's revenue grow year over year in Q2 2026?
CV Sciences's revenue fell $635K (-18%) from $3.6M in Q2 2025 to $3.0M in Q2 2026.